The first two patients to receive a CRISPR-based treatment for the inherited blood disorders sickle cell disease and beta thalassemia have benefited from the experimental therapy and experienced only temporary and treatable side effect.

https://www.statnews.com/2019/11/19/first-crispr-treatment-for-blood-diseases-shows-early-benefits/